NLEM

Revenue growth to moderate to 8-10 per cent in FY2025, post a healthy 13-14 per cent YoY expansion in FY2024

Revenues of ICRA’s sample set to grow by 7-9 per cent in FY2024; OPM to stabilise at 20.5-21.5 per cent in FY2024

While Mankind Pharma’s IPO re-validates the long-term potential of the India Pharma Inc narrative, it won’t take much for the…

Anti-infectives like Ivermectin, Mupirocin and Meropenem have been added to the list, taking the total drugs under it to 384

Raheel Shah, Director, BDR Pharma, explains the pinch that the consumers will feel as a result of the price hike of over 800…

The ceiling prices, inclusive of Wholesale Price Index (WPI) at 10.76 per cent for the year 2021 over 2020, are applicable with…

The panel also recommended exemption of basic customs duty and GST on medicines and medical devices for fighting COVID-19

Sichuan Airlines recently suspended all its cargo flights to India for 15 days, causing major disruption to private traders'…

Also recommends inclusion of different formulations of insulin in the upcoming NLEM

According to a report in Centrum Broking, the domestic pharma market will gain from price increase, volume growth and new product…